ArticleJournal of tropical medicine2026
Factors Associated With Viral Load Suppression Among Adolescents and Young Adults Living With HIV on ART in Rwanda: Data From Rwanda HIV Case-Based Surveillance, 2019-2025.
Article in Journal of tropical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adolescents and young adults living with HIV (AYALHIV) in sub-Saharan Africa have lower viral load (VL) suppression (VLS) rates than older adults. Rwanda lacks national-level evidence on predictors of VLS in this age group. This study assessed demographic and clinical determinants of VLS among AYALHIV aged 15-24 years on antiretroviral therapy (ART), using national case-based surveillance (CBS) data. Methods: We conducted a retrospective cohort analysis of AYALHIV enrolled in Rwanda's CBS system who initiated ART between January 2019 and December 2025 and had a documented VL at least six months after ART initiation. The primary outcome, VLS, was defined as VL ≤ 1000 copies/mL. Modified Poisson regression with robust, facility-clustered standard errors was used to estimate prevalence ratios (PRs); missing covariate data were addressed using multiple imputation ( Results: A total of 4140 participants across 458 health facilities were included. Most were female (88%) and aged 20-24 years (90.7%); 91.6% were initiated on a dolutegravir-based regimen, 98.7% demonstrated good adherence, and overall, 96.1% achieved VLS. In multivariable analysis, good adherence was the only factor independently associated with VLS, corresponding to a 70% higher prevalence of suppression relative to bad/moderate adherence (adjusted PR = 1.70; 95% CI: 1.33-2.19; Conclusion: VLS among AYALHIV aged 15-24 years engaged in Rwanda's HIV care program is high, exceeding the UNAIDS 95% target. Country HIV programs should prioritize adherence-focused interventions and proactively address underlying barriers to adherence in order to sustain optimal treatment outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.